Maryland Bids > Bid Detail

DEVELOPMENT OF NOVEL NANOTHERAPEUTICS TO COMBAT PNEUMONIC PLAGUE

Agency: DEPT OF DEFENSE
Level of Government: Federal
Category:
  • A - Research and development
Opps ID: NBD00159933008489838
Posted Date: Mar 9, 2023
Due Date: Mar 23, 2023
Solicitation No: HT9425-23-KKL-0002
Source: https://sam.gov/opp/d5274ab6fc...
Follow
DEVELOPMENT OF NOVEL NANOTHERAPEUTICS TO COMBAT PNEUMONIC PLAGUE
Active
Contract Opportunity
Notice ID
HT9425-23-KKL-0002
Related Notice
Department/Ind. Agency
DEPT OF DEFENSE
Sub-tier
DEPT OF THE ARMY
Major Command
MEDCOM
Sub Command
USAMRAA
Office
W4PZ USA MED RSCH ACQUIS ACT
Looking for contract opportunity help?

Procurement Technical Assistance Centers (PTACs) are an official government contracting resource for small businesses. Find your local PTAC (opens in new window) for free government expertise related to contract opportunities.

General Information
  • Contract Opportunity Type: Sources Sought (Original)
  • All Dates/Times are: (UTC-05:00) EASTERN STANDARD TIME, NEW YORK, USA
  • Original Published Date: Mar 09, 2023 03:26 pm EST
  • Original Response Date: Mar 23, 2023 01:00 pm EDT
  • Inactive Policy: 15 days after response date
  • Original Inactive Date:
  • Initiative:
    • None
Classification
  • Original Set Aside:
  • Product Service Code: AJ12 - General Science and Technology R&D Services; General science and technology; Applied Research
  • NAICS Code:
    • 541713 - Research and Development in Nanotechnology
  • Place of Performance:
    Frederick , MD 21702
    USA
Description

The Government intends to award an Indefinite Delivery/Indefinite Quantity (IDIQ) contract for novel nanotherapeutic approaches targeting outer membrane proteins for the treatment of pneumonic plague (and potentially other infectious microbial organisms or toxins) for assessment in in vitro and in vivo assays support. These services include, but are not limited to production of high-quality recombinant proteins from bacteria, viruses, or toxins; vaccinating appropriate animal species (i.e. camelids and bovines) to generate the material needed to engineer completely novel nanotherapeutics; perform in vitro testing of nanotherapeutic characteristics in order to refine molecules and promote down-selection, provide material in sufficient quantity and appropriate quality for in vitro and in vivo studies (e.g. mice and non-human primates), engineer or formulate down-selected nanotherapeutics for different routes of administration in vivo (e.g., intramuscular or intravenous, etc.).


Attachments/Links
Contact Information
Contracting Office Address
  • BLDG 820 PBO 820 CHANDLER STREET
  • FORT DETRICK , MD 21702-5014
  • USA
Primary Point of Contact
Secondary Point of Contact
History
  • Mar 09, 2023 03:26 pm ESTSources Sought (Original)

TRY FOR FREE

Not a USAOPPS Member Yet?

Get unlimited access to thousands of active local, state and federal government bids and awards in All 50 States.

Start Free Trial Today >